Video Experimental Relacionado
Updated: Jan 13, 2026
10:38
Deciphering and Imaging Pathogenesis and Cording of Mycobacterium abscessus in Zebrafish Embryos
Published on: September 9, 2015
10.9K
Absceso pulmonar como efecto adverso del Risankizumab
Zarif Kazi1, Stuart Jesin1, Samir Ghimire1
1Internal Medicine, Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
European clinical respiratory journal
|January 12, 2026
Resumen
Este caso destaca una posible relación entre Risankizumab (una terapia biológica) e infecciones pulmonares graves. Se necesita más investigación para comprender los riesgos infecciosos asociados con el uso prolongado de Risankizumab.
Área de la Ciencia:
- Inmunología
- Neumología
- Enfermedades Infecciosas
Sus antecedentes:
- Risankizumab es una terapia biológica utilizada durante períodos prolongados.
- Es crucial caracterizar los riesgos infecciosos asociados con Risankizumab.
- Los pacientes en tratamiento a largo plazo con Risankizumab pueden tener una mayor susceptibilidad a las infecciones.
Objetivo del estudio:
- Informar un caso de absceso pulmonar en un paciente tratado con Risankizumab.
- Investigar posibles asociaciones entre Risankizumab e infecciones oportunistas.
- Contribuir a la comprensión del perfil de seguridad de Risankizumab en cuanto a complicaciones infecciosas.
Principales métodos:
- Presentación de un caso de un hombre de 30 años con psoriasis y alopecia en tratamiento con Risankizumab.
- La presentación clínica incluyó dolor torácico pleurítico, tos, hemoptisis, fiebre y mialgias.
- El estudio diagnóstico incluyó tomografías computarizadas, cultivos de esputo para AFB, cultivos de líquido pleural y ensayo Xpert MTB/RIF.
Principales resultados:
- Se identificó una gran lesión cavitaria y derrame pleural en las tomografías computarizadas.
- El estudio infeccioso descartó tuberculosis pero identificó Staphylococcus aureus resistente a la meticilina y Mycobacterium avium.
- El paciente fue tratado con doxiciclina y se sometió a decorticación por VATS.
Conclusiones:
- El caso sugiere una posible asociación entre Risankizumab y el desarrollo de absceso pulmonar.
- Risankizumab puede contribuir a la inmunosupresión, aumentando el riesgo de infecciones graves.
- Este caso subraya la importancia de monitorizar las infecciones en pacientes que reciben tratamiento con Risankizumab.
Videos de Conceptos Relacionados
01:23Rheumatic Heart Disease I: Introduction
417
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
417
01:21Drugs for Treatment of Constipation-Predominant IBS
688
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
688
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
448
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
448
01:30Inflammatory Bowel Disease II: Crohn's Disease
943
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
943